AU2018269585B2 - BTLA agonist antibodies and uses thereof - Google Patents

BTLA agonist antibodies and uses thereof Download PDF

Info

Publication number
AU2018269585B2
AU2018269585B2 AU2018269585A AU2018269585A AU2018269585B2 AU 2018269585 B2 AU2018269585 B2 AU 2018269585B2 AU 2018269585 A AU2018269585 A AU 2018269585A AU 2018269585 A AU2018269585 A AU 2018269585A AU 2018269585 B2 AU2018269585 B2 AU 2018269585B2
Authority
AU
Australia
Prior art keywords
ser
seq
leu
val
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018269585A
Other languages
English (en)
Other versions
AU2018269585A1 (en
Inventor
Shane Krummen ATWELL
Victor H. Obungu
Andrew Charles VENDEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2018269585A1 publication Critical patent/AU2018269585A1/en
Application granted granted Critical
Publication of AU2018269585B2 publication Critical patent/AU2018269585B2/en
Priority to AU2021277743A priority Critical patent/AU2021277743A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018269585A 2017-05-19 2018-05-11 BTLA agonist antibodies and uses thereof Active AU2018269585B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021277743A AU2021277743A1 (en) 2017-05-19 2021-12-02 BTLA Agonist Antibodies And Uses Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
US62/508,510 2017-05-19
PCT/US2018/032218 WO2018213113A1 (en) 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021277743A Division AU2021277743A1 (en) 2017-05-19 2021-12-02 BTLA Agonist Antibodies And Uses Thereof

Publications (2)

Publication Number Publication Date
AU2018269585A1 AU2018269585A1 (en) 2019-10-31
AU2018269585B2 true AU2018269585B2 (en) 2021-09-02

Family

ID=62245543

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018269585A Active AU2018269585B2 (en) 2017-05-19 2018-05-11 BTLA agonist antibodies and uses thereof
AU2021277743A Abandoned AU2021277743A1 (en) 2017-05-19 2021-12-02 BTLA Agonist Antibodies And Uses Thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021277743A Abandoned AU2021277743A1 (en) 2017-05-19 2021-12-02 BTLA Agonist Antibodies And Uses Thereof

Country Status (26)

Country Link
US (2) US10604573B2 (enExample)
EP (1) EP3625257A1 (enExample)
JP (2) JP6790304B2 (enExample)
KR (3) KR102294051B1 (enExample)
CN (3) CN110621699B (enExample)
AR (1) AR111752A1 (enExample)
AU (2) AU2018269585B2 (enExample)
BR (1) BR112019021547A2 (enExample)
CA (2) CA3184628A1 (enExample)
CL (1) CL2019003215A1 (enExample)
CO (1) CO2019012756A2 (enExample)
CR (1) CR20190521A (enExample)
DO (1) DOP2019000293A (enExample)
EA (1) EA201992460A1 (enExample)
EC (1) ECSP19082184A (enExample)
JO (1) JOP20190261A1 (enExample)
MA (1) MA49133A (enExample)
MX (1) MX381033B (enExample)
MY (2) MY197425A (enExample)
NZ (1) NZ758360A (enExample)
PE (1) PE20191843A1 (enExample)
PH (1) PH12019502575A1 (enExample)
SA (1) SA519410534B1 (enExample)
TW (4) TWI804044B (enExample)
WO (1) WO2018213113A1 (enExample)
ZA (1) ZA201906954B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
IL302135A (en) * 2020-10-23 2023-06-01 Anaptysbio Inc B and t lymphocyte attenuator (btla) modulators and method of using same
MX2024009326A (es) * 2022-01-29 2024-08-06 Hifibio Inc Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer.
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014438A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
EP1560593B1 (en) * 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CA2669921A1 (en) * 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
JP2018521959A (ja) * 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP7227007B2 (ja) * 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014438A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla

Also Published As

Publication number Publication date
JOP20190261A1 (ar) 2019-11-05
TW201946932A (zh) 2019-12-16
JP2021019642A (ja) 2021-02-18
KR20210106033A (ko) 2021-08-27
US20200239578A1 (en) 2020-07-30
AU2018269585A1 (en) 2019-10-31
CN110621699A (zh) 2019-12-27
TWI747043B (zh) 2021-11-21
KR102294051B1 (ko) 2021-08-27
CA3184628A1 (en) 2018-11-22
CL2019003215A1 (es) 2020-04-13
US20180334502A1 (en) 2018-11-22
TW202334237A (zh) 2023-09-01
JP2020518288A (ja) 2020-06-25
MY198277A (en) 2023-08-18
CO2019012756A2 (es) 2020-01-17
KR20220158847A (ko) 2022-12-01
CN117402245A (zh) 2024-01-16
TW201904991A (zh) 2019-02-01
PE20191843A1 (es) 2019-12-31
ZA201906954B (en) 2021-06-30
MY197425A (en) 2023-06-16
MX2019013604A (es) 2019-12-18
MA49133A (fr) 2020-03-25
DOP2019000293A (es) 2019-12-15
CN110621699B (zh) 2023-10-31
EA201992460A1 (ru) 2020-03-18
SA519410534B1 (ar) 2023-11-08
TWI804044B (zh) 2023-06-01
AR111752A1 (es) 2019-08-14
JP6790304B2 (ja) 2020-11-25
ECSP19082184A (es) 2019-11-30
PH12019502575A1 (en) 2020-07-13
BR112019021547A2 (pt) 2020-05-12
KR20190140969A (ko) 2019-12-20
TW202233681A (zh) 2022-09-01
US11396545B2 (en) 2022-07-26
US10604573B2 (en) 2020-03-31
JP7072622B2 (ja) 2022-05-20
CN117402244A (zh) 2024-01-16
CR20190521A (es) 2020-01-06
TWI677504B (zh) 2019-11-21
CA3064518A1 (en) 2018-11-22
MX381033B (es) 2025-03-12
NZ758360A (en) 2022-10-28
EP3625257A1 (en) 2020-03-25
WO2018213113A1 (en) 2018-11-22
AU2021277743A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
AU2018269585B2 (en) BTLA agonist antibodies and uses thereof
CN112513091B (zh) 抗il36r抗体
KR102772851B1 (ko) Trem2 항원 결합 단백질 및 이의 용도
AU2024200534A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
KR102025848B1 (ko) 항―ｎｇｆ 조성물 및 그의 용도
KR102417687B1 (ko) Tl1a 항체 및 그의 용도
US9708402B2 (en) Anti-BAFF-anti-IL-17 bispecific antibodies
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
AU2014226093A1 (en) Anti-TNF-anti-IL-17 bispecific antibodies
TW201023890A (en) Antagonists of IL-6 to prevent or thrombosis
CN106795223B (zh) 针对Fcγ受体IIB及Fcε受体的抗体
AU2019339334B2 (en) CD200R agonist antibodies and uses thereof
AU2019395325B2 (en) Anti-Alpha-Synuclein Antibodies and Uses Thereof
KR101943724B1 (ko) Ang2 항체
CN111918879B (zh) 用于治疗表达LMA的癌症和自身免疫疾病的抗λ骨髓瘤抗原(LMA)结合蛋白
KR102895164B1 (ko) 항-il36r 항체
IL317720A (en) Anti-thiazepine monoclonal antibody and its use
HK40016006A (en) Trem2 antigen binding proteins and uses thereof
HK40015870A (en) Bispecific antigen binding molecule for a costimulatory tnf receptor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)